Yaochen Cao

Nov 9, 2024 | onlinelibrary.wiley.com | Xin Chen |Denis Delic |Yvonne Liu |Yaochen Cao

Plain English Summary This study explores a new treatment strategy for kidney disease, specifically chronic kidney disease (CKD). We tested a combination of two drugs that increase levels of a beneficial molecule called cGMP, known to reduce kidney fibrosis (scarring). Using a rat model of CKD, the combination treatment significantly decreased fibrosis and regulated fibrosis-related genes without affecting blood pressure or immune cell levels in the kidneys.